| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Outline of Final Research Achievements |
EML4 is transcriptionally active, but not ALK in the normal lung, and EML4-ALK translocation in lung cancer leads to activate the transcription of ALK kinase by the EML4 promoter. Therefore, ALK transcription has different patterns between 5’ and 3’ ends when the tumor has the translocation, and the difference can be utilized for a screening tool for the translocation. We examined 15 and 40 of ALK rearranged and wild type tumors, respectively, and found this method could work well with quantitative RT-PCR. Similarly, we applied this method to ROS and RET translocations, but the gene was expressed in the normal lung tissues. So, we defined the appropriate cut-off values, and also found the method could be used as a screening. Furthermore, we established immunohistochemistry to detect ROS1-rearranged tumors, and reported the results (Clin Lung Cancer 2015).
|
